Department of Hematology & Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Department of Transfusion Medicine, The University of Tokyo Hospital, Tokyo, Japan.
Stem Cells. 2017 Jul;35(7):1835-1848. doi: 10.1002/stem.2640. Epub 2017 May 23.
Myelotoxic injury, such as chemotherapeutic agents and ionizing radiation, unlocks the vigorous power of hematopoietic stem cells (HSCs) to replenish the hematopoietic system, making quiescent HSCs enter the cell cycle. Considering that both HSC-intrinsic and -extrinsic mechanisms enforce quiescence of HSCs, the drastic change in bone marrow (BM) environment after injury, represented by massive expansion of BM adipocytes, might trigger HSC activation. BM adipocytes, the major cellular component in the ablated marrow, however, reportedly suppress proliferation of hematopoietic cells, which may indicate the BM adipocytogenesis is an irrational response of injured organism. Given that adipose tissue is an endocrine organ with pleiotropic functions, we hypothesized that adipocyte-derived factors, especially adiponectin, an anti-inflammatory adipokine involved in regulation of granulopoiesis, are implicated in HSC activation. Myeloablative intervention increased BM adiponectin by multiple mechanisms, including adipocyte expansion and increased diffusion from the blood. Adiponectin-null (Adipoq ) mice showed delayed hematopoietic recovery after BM injury, with Adipoq HSCs more quiescent and defective in mammalian target of rapamycin complex 1 (mTORC1) activation. Recombinant adiponectin promoted not only HSC activation in vivo but cytokine-induced activation in vitro, and shortened the time for exit from quiescence in an mTORC1-dependent manner. These data illustrate a scarcely-reported example of a cell-extrinsic factor, adiponectin, enhancing quiescence exit of HSCs, and subsequent hematopoietic recovery. Our findings also highlight adipocytes as a source of adiponectin to ensure the proliferative burst of hematopoietic cells in ablated marrow. Stem Cells 2017;35:1835-1848.
骨髓毒性损伤,如化疗药物和电离辐射,会激活造血干细胞(HSCs)的活力,使其补充造血系统,使静止的 HSCs 进入细胞周期。考虑到 HSC 内在和外在机制都能维持 HSCs 的静止状态,损伤后骨髓(BM)环境的剧烈变化,表现为 BM 脂肪细胞的大量扩增,可能会触发 HSC 的激活。然而,BM 脂肪细胞是骨髓中主要的细胞成分,据报道,它会抑制造血细胞的增殖,这可能表明 BM 脂肪生成是受损机体的一种不合理反应。鉴于脂肪组织是一种具有多种功能的内分泌器官,我们假设脂肪细胞衍生的因子,特别是脂联素,一种参与粒细胞生成调节的抗炎脂肪因子,与 HSC 激活有关。骨髓清除性干预通过多种机制增加了 BM 中的脂联素,包括脂肪细胞的扩张和从血液中扩散增加。脂肪细胞缺失(Adipoq )的小鼠在骨髓损伤后造血恢复延迟,Adipoq HSCs 更为静止,mTORC1 激活缺陷。重组脂联素不仅能促进体内 HSC 的激活,还能促进体外细胞因子诱导的激活,并以 mTORC1 依赖的方式缩短静止退出的时间。这些数据说明了一个鲜为人知的例子,即细胞外在因子脂联素增强了 HSCs 的静止退出,随后促进了造血恢复。我们的发现还强调了脂肪细胞作为脂联素的来源,以确保造血细胞在骨髓清除后的增殖爆发。干细胞 2017;35:1835-1848.